Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges

Overview

Journal J Pharm Sci

Publisher Elsevier

Specialties Pharmacology
Pharmacy

Date 2016 Apr 6

PMID 27044944

Citations 29

Authors

Wim Jiskoot

Grzegorz Kijanka

Theodore W Randolph

John F Carpenter

Atanas V Koulov

Hanns-Christian Mahler

Marisa K Joubert

Vibha Jawa

Linda O Narhi

Affiliations

Soon will be listed here.

Abstract

The success of clinical and commercial therapeutic proteins is rapidly increasing, but their potential immunogenicity is an ongoing concern. Most of the studies that have been conducted over the past few years to examine the importance of various product-related attributes (in particular several types of aggregates and particles) and treatment regimen (such as dose, dosing schedule, and route of administration) in the development of unwanted immune responses have utilized one of a variety of mouse models. In this review, we discuss the utility and drawbacks of different mouse models that have been used for this purpose. Moreover, we summarize the lessons these models have taught us and some of the challenges they present. Finally, we provide recommendations for future research utilizing mouse models to improve our understanding of critical factors that may contribute to protein immunogenicity.

Citing Articles

An overview of ELISA: a review and update on best laboratory practices for quantifying peptides and proteins in biological fluids.

Aydin S, Emre E, Ugur K, Aydin M, Sahin I, Cinar V J Int Med Res. 2025; 53(2):3000605251315913.

PMID: 39922798 PMC: 11808753. DOI: 10.1177/03000605251315913.

Mitigation Strategies against Antibody Aggregation Induced by Oleic Acid in Liquid Formulations.

Zurcher D, Wuchner K, Arosio P Mol Pharm. 2024; 21(11):5761-5771.

PMID: 39444106 PMC: 11539069. DOI: 10.1021/acs.molpharmaceut.4c00754.

Production of highly cytotoxic and low immunogenic L-asparaginase from Stenotrophomonas maltophilia EMCC2297.

Abdelrazek N, Saleh S, Raafat M, Ali A, Aboulwafa M AMB Express. 2024; 14(1):51.

PMID: 38704453 PMC: 11069494. DOI: 10.1186/s13568-024-01700-9.

A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the Clinic.

Cohen J, Brych S, Prabhu S, Bi V, Elbaradei A, Tokuda J Pharm Res. 2024; 41(4):651-672.

PMID: 38519817 DOI: 10.1007/s11095-024-03678-2.

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics.

Sun R, Qian M, Zhang X MAbs. 2024; 16(1):2324836.

PMID: 38512798 PMC: 10962608. DOI: 10.1080/19420862.2024.2324836.

References

Moussa E, Panchal J, Moorthy B, Blum J, Joubert M, Narhi L . Immunogenicity of Therapeutic Protein Aggregates. J Pharm Sci. 2016; 105(2):417-430. DOI: 10.1016/j.xphs.2015.11.002. View

Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A . Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler. 2007; 13(2):208-14. DOI: 10.1177/1352458506070762. View

Jawa V, Cousens L, Awwad M, Wakshull E, Kropshofer H, De Groot A . T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol. 2013; 149(3):534-55. DOI: 10.1016/j.clim.2013.09.006. View

Torosantucci R, Brinks V, Kijanka G, Halim L, Sauerborn M, Schellekens H . Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin. J Pharm Sci. 2014; 103(5):1367-74. DOI: 10.1002/jps.23935. View

van Beers M, Jiskoot W, Schellekens H . On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res. 2010; 30(10):767-75. DOI: 10.1089/jir.2010.0086. View

Pisal D, Kosloski M, Middaugh C, Bankert R, Balu-Iyer S . Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. J Pharm Sci. 2012; 101(6):2055-65. PMC: 3774159. DOI: 10.1002/jps.23091. View

Freitag A, Shomali M, Michalakis S, Biel M, Siedler M, Kaymakcalan Z . Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice. Pharm Res. 2014; 32(2):430-44. DOI: 10.1007/s11095-014-1472-6. View

Shultz L, Brehm M, Garcia-Martinez J, Greiner D . Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012; 12(11):786-98. PMC: 3749872. DOI: 10.1038/nri3311. View

Fradkin A, Mozziconacci O, Schoneich C, Carpenter J, Randolph T . UV photodegradation of murine growth hormone: chemical analysis and immunogenicity consequences. Eur J Pharm Biopharm. 2014; 87(2):395-402. PMC: 4066668. DOI: 10.1016/j.ejpb.2014.04.005. View

10.

Ottesen J, Nilsson P, Jami J, Weilguny D, Duhrkop M, Bucchini D . The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia. 1994; 37(12):1178-85. DOI: 10.1007/BF00399790. View

11.

Moore W, Leppert P . Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab. 1980; 51(4):691-7. DOI: 10.1210/jcem-51-4-691. View

12.

Brinks V, Weinbuch D, Baker M, Dean Y, Stas P, Kostense S . Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharm Res. 2013; 30(7):1719-28. DOI: 10.1007/s11095-013-1062-z. View

13.

Brinks V, Jiskoot W, Schellekens H . Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011; 28(10):2379-85. PMC: 3170476. DOI: 10.1007/s11095-011-0523-5. View

14.

van Mierlo G, Cnubben N, Wouters D, Wolbink G, Hart M, Rispens T . The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab. J Immunotoxicol. 2013; 11(1):62-71. DOI: 10.3109/1547691X.2013.796023. View

15.

Ratner R, Phillips T, Steiner M . Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. Diabetes. 1990; 39(6):728-33. DOI: 10.2337/diab.39.6.728. View

16.

Gilli F, van Beers M, Marnetto F, Jiskoot W, Bertolotto A, Schellekens H . Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera. J Immunol Methods. 2008; 336(2):119-26. DOI: 10.1016/j.jim.2008.04.002. View

17.

van Beers M, Bardor M . Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J. 2012; 7(12):1473-84. DOI: 10.1002/biot.201200065. View

18.

Johnson R, Jiskoot W . Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations. J Pharm Sci. 2012; 101(10):3586-92. DOI: 10.1002/jps.23248. View

19.

Dintzis R, Okajima M, Middleton M, Greene G, Dintzis H . The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol. 1989; 143(4):1239-44. View

20.

Braun A, Kwee L, Labow M, Alsenz J . Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res. 1997; 14(10):1472-8. DOI: 10.1023/a:1012193326789. View